TY - JOUR T1 - Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01655-2018 VL - 53 IS - 4 SP - 1801655 AU - Cottin, Vincent AU - Azuma, Arata AU - Raghu, Ganesh AU - Stansen, Wibke AU - Stowasser, Susanne AU - Schlenker-Herceg, Rozsa AU - Kolb, Martin Y1 - 2019/04/01 UR - //www.qdcxjkg.com/content/53/4/1801655.abstract N2 - Emphysema is a common comorbidity in patients with idiopathic pulmonary fibrosis (IPF) [1–4].受约束和阻塞效果综合作用影响,伴生IPC和Emphysema病人通常有正常或高强制关键容量,但排散容量下降[5]Data from retrospective studies have demonstrated that lung function decline is attenuated in patients with IPF who have emphysema [6], with some evidence suggesting a threshold for extent of emphysema beyond which FVC decline is reduced [7].In post hoc analyses of pooled data from the INPULSIS trials, the treatment effect of nintedanib versus placebo was not influenced by the presence of emphysema (yes versus no) or by FEV1/FVC ratio (≥0.7 to ≤0.8 versus >0.8) at baseline http://ow.ly/Gmwn30nwPY1The authors acknowledge the contribution of David M. Hansell, formerly of the Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK, for reading the HRCT scans in the INPULSIS trials.医学写作辅助由Boeringer Ingelheim提供财政支助,由联合王国伦敦FleshmanHillardFishburn Ltd的JulieFleming和WendyMorris提供作者完全负责所有内容和编辑决策,参与手稿开发所有阶段并核准最终版本ER-